한글목차

침윤에 사용되는 POSIMIR(SABER-부피바카인, 구명 POSIDUR)은 660mg의 강력한 부피바카인 기제와 혁신적인 SABER 플랫폼 기술을 조합한 신규의 독자 제품이며, 성인에서 비오피오이드계 국소진통제의 3일간에 걸친 지속적인 투여를 가능하게 합니다. 견봉하 제압술 후 72시간까지 수술후 진통에 적응됩니다.

약제명의 변경이 정해진 이유는 FDA가 POSIDUR에 우려를 보였기 때문입니다. 그렇지 않은 경우 추가 안전성 시험이 필요하다고 말했습니다.

작용 메커니즘

부피바카인은 신경의 전기적 흥분의 역치를 상승시켜, 신경 임펄스의 전파를 늦추고, 활동 전위의 상승 속도를 저하시킴으로써, 신경 임펄스의 발생과 전도를 차단합니다. 마취의 진행은 이환된 신경 섬유의 직경, 수초, 전도 속도와 관련이 있습니다. 고유 감각,(5) 골격근 긴장입니다.

본 보고서에서는 주요 7개국의 POSIMIR 시장에 대해 조사했으며,, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술후 통증에 있어서의 POSIMIR의 개요

• 제품 상세
• 임상 개발
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 POSIMIR 시장 평가

• 수술 후 통증에서 POSIMIR 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"POSIMIR Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about POSIMIR for Postoperative pain in the seven major markets. A detailed picture of the POSIMIR for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the POSIMIR for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POSIMIR market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

POSIMIR (SABER-bupivacaine, also previously known as POSIDUR) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. It contains a local amide anesthetic and is indicated in adults for administration into the subacromial space under direct arthroscopic visualization to produce postsurgical analgesia for up to 72 h following arthroscopic subacromial decompression.

The company decided to change the drug's name because the FDA was concerned with POSIDUR. In 2014, the US regulator told the company that investigators did not provide sufficient data to prove that it could be safely administered and would need additional safety studies. This came 2 years after the program failed an efficacy test in a late-stage study.

Mechanism of action

Bupivacaine blocks the generation and the conduction of nerve impulses by increasing the threshold for electrical excitation in the nerve, slowing the nerve impulses propagation, and reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of a loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the POSIMIR description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on POSIMIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the POSIMIR research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around POSIMIR.
• The report contains forecasted sales of POSIMIR for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for POSIMIR in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POSIMIR Analytical Perspective by DelveInsight

• In-depth POSIMIR Market Assessment

This report provides a detailed market assessment of POSIMIR for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• POSIMIR Clinical Assessment

The report provides the clinical trials information of POSIMIR for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POSIMIR dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to POSIMIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POSIMIR in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of POSIMIR from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POSIMIR in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of POSIMIR?
• What is the clinical trial status of the study related to POSIMIR in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POSIMIR development?
• What are the key designations that have been granted to POSIMIR for Postoperative pain?
• What is the forecasted market scenario of POSIMIR for Postoperative pain?
• What are the forecasted sales of POSIMIR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to POSIMIR for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. POSIMIR Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. POSIMIR Market Assessment

• 5.1. Market Outlook of POSIMIR in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of POSIMIR in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of POSIMIR in the United States for Postoperative pain
  • 5.3.2. Market Size of POSIMIR in Germany for Postoperative pain
  • 5.3.3. Market Size of POSIMIR in France for Postoperative pain
  • 5.3.4. Market Size of POSIMIR in Italy for Postoperative pain
  • 5.3.5. Market Size of POSIMIR in Spain for Postoperative pain
  • 5.3.6. Market Size of POSIMIR in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of POSIMIR in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options